Mitch Gold, MD, joined Frazier Life Sciences as a Venture Partner in 2025, bringing over 25 years of biotech leadership experience. He was Co-Founder, CEO, and Executive Chairman of Alpine Immune Sciences, leading the company from its 2015 founding through its $4.9 billion acquisition by Vertex Pharmaceuticals in 2024. Prior to that, he founded Alpine Biosciences, which was acquired by Cascadian Therapeutics and later SGEN. Both companies were seeded by Alpine Bioventures, a venture firm he launched in 2012.
Earlier in his career, Mitch served as CEO and Chairman of Dendreon Corporation, where he led the development of PROVENGE®, the first FDA-approved cell-based cancer therapy. He holds an MD from Rush Medical College, completed his urology residency at the University of Washington, and earned a BS in Biology from the University of Wisconsin–Madison.